ORIGINAL ARTICLE
Prostate cancer with different ERG status may show different FOXP3-positive cell numbers
Submission date: 2016-11-13
Acceptance date: 2016-11-27
Publication date: 2017-02-10
Pol J Pathol 2016;67(4):313-317
KEYWORDS
TOPICS
ABSTRACT
Prostatic carcinoma is the most frequent cancer in males in the Western world. A significant proportion of these cancers have a recurrent translocation involving ETS family genes, which leads to the overexpression of ERG transcription factor. Prostate cancers, which bear this mutation, differ in a number of features, including tumor microenvironment. One of the components of the tumor microenvironment is FOXP3 positive lymphocytes, which may participate in breaking immunosurveillance and promoting tumor growth.
The aim of the study was to analyze the relationships between ERG expression, number of FOXP3 positive cells and other features of the tumor.
The study group consisted of 65 cases. Tissue microarrays composed of 2 mm tissue cores were used for immunohistological evaluation. Immunohistochemistry for ERG and FOXP3 was performed according to the routinely applied protocol. The FOXP3 positive cells were counted and the results were expressed as the number of cells per mm2.
The average number of FOXP3 positive cells was 33.30/mm2 for all cases, 21.43/mm2 for the ERG negative and 42.28/mm2 for the ERG positive group (p < 0.02). There were no significant relationships between FOXP3 positive cell count and any other parameters studied.
Our results suggest that the immune response may differ between ERG negative and ERG positive prostatic carcinomas.
The aim of the study was to analyze the relationships between ERG expression, number of FOXP3 positive cells and other features of the tumor.
The study group consisted of 65 cases. Tissue microarrays composed of 2 mm tissue cores were used for immunohistological evaluation. Immunohistochemistry for ERG and FOXP3 was performed according to the routinely applied protocol. The FOXP3 positive cells were counted and the results were expressed as the number of cells per mm2.
The average number of FOXP3 positive cells was 33.30/mm2 for all cases, 21.43/mm2 for the ERG negative and 42.28/mm2 for the ERG positive group (p < 0.02). There were no significant relationships between FOXP3 positive cell count and any other parameters studied.
Our results suggest that the immune response may differ between ERG negative and ERG positive prostatic carcinomas.
REFERENCES (31)
1.
Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2.
Strzepek A, Kaczmarczyk K, Bialas M, et al. ERG positive prostatic cancer may show a more angiogenetic phenotype. Pathol Res Pract 2014; 210: 897-900.
3.
Galazka K, Wicherek L, Pitynski K, et al. Changes in the subpopulation of CD25+ CD4+ and FOXP3+ regulatory T cells in decidua with respect to the progression of labor at term and the lack of analogical changes in the subpopulation of suppressive B7-H4 macrophages – a preliminary report. Am J Reprod Immunol 2009; 61: 136-146.
4.
Merlo A, Casalini P, Carcangiu ML, et al. FOXP3 expression and overall survival in breast cancer. J Clin Oncol 2009; 27: 1746-1752.
5.
Petersen RP, Carnpa MJ, Sperlazza J, et al. Tumor infiltrating FOXP3(+) regulatory T-cells are associated with recurrence in pathologic stage INSCLC patients. Cancer 2006; 107: 2866-2872.
6.
Salama P, Phillips M, Grieu F, et al. Tumor-infiltrating FOXP3(+) T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol 2009; 27: 186-192.
7.
Epstein JI, Allsbrook WC, Jr., Amin MB, et al. The 2005 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol 2005; 29: 1228-1242.
8.
Fine SW, Amin MB, Berney DM, et al. A contemporary update on pathology reporting for prostate cancer: biopsy and radical prostatectomy specimens. Eur Urol 2012; 62: 20-39.
9.
Epstein JI, Amin MB, Beltran H, et al. Proposed morphologic classification of prostate cancer with neuroendocrine differentiation. Am J Surg Pathol 2014; 38: 756-767.
10.
Epstein JI, Carmichael MJ, Pizov G, et al. Influence of capsular penetration on progression following radical prostatectomy: a study of 196 cases with long-term followup. J Urol 1993; 150: 135-141.
11.
Kaczmarczyk K, Dyduch G, Bialas M, et al. Frequency of ERG-positive prostate carcinoma in Poland. Pol J Pathol 2013; 64: 175-179.
12.
Wojciechowska U, Didkowska J. Cancer incidence and mortality in Poland. National Cancer Registry. Centrum Onkologii – Instytut im. Marii Skłodowskiej-Curie, Warsaw.
13.
Klotz L. Cancer overdiagnosis and overtreatment. Curr Opin Urol 2012; 22: 203-209.
14.
Loeb S, Bjurlin MA, Nicholson J, et al. Overdiagnosis and overtreatment of prostate cancer. Eur Urol 2014; 65: 1046-1055.
15.
Baxevanis CN, Papamichail M, Perez SA. Prostate cancer vaccines: the long road to clinical application. Cancer Immunol Immun 2015; 64: 401-408.
16.
Miłek K, Kaczmarczyk-Sekuła K, Strzepek A, et al. Mast cells influence neoangiogenesis in prostatic cancer independently of ERG status. Pol J Pathol 2016; 67: 244-249.
17.
Sonpavde G, Pond GR, Armstrong AJ, et al. prognostic impact of the neutrophil-to-lymphocyte ratio in men with metastatic castration-resistant prostate cancer. Clin Genitourin Cancer 2014; 12: 317-324.
18.
Pinato DJ. Cancer-related inflammation: an emerging prognostic domain in metastatic castration-resistant prostate carcinoma. Cancer 2014; 120: 3272-3274.
19.
Brennen WN, Denmeade SR, Isaacs JT. Mesenchymal stem cells as a vector for the inflammatory prostate microenvironment. Endocr Relat Cancer 2013; 20: R269-R290.
20.
Rubinkiewicz M, Migaczewski M, Hankus J, et al. The number of regulatory Foxp3+ T-cells in different stages of malignant transformation of large intestinal polyps. Adv Med Sci 2016; 61: 306-310.
21.
Yokokawa J, Remondo C, Gulley JL, et al. Enhanced functionality of CD4(+)CD25(high)FoxP3(+) regulatory T cells in the peripheral blood of patients with prostate cancer. Clin Cancer Res 2008; 14: 1032-1040.
22.
Ebelt K, Babaryka G, Figel AM, et al. Dominance of CD4(+) lymphocytic infiltrates with disturbed effector cell characteristics in the tumor microenvironment of prostate carcinoma. Prostate 2008; 68: 1-10.
23.
Ebelt K, Babaryka G, Frankenberger B, et al. Prostate cancer lesions are surrounded by FOXP3(+), PD-1(+) and B7-H1(+) lymphocyte clusters. Eur J Cancer 2009; 45: 1664-1672.
24.
Miller AM, Lundberg K, Ozenci V, et al. CD4+CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. J Immunol 2006; 177: 7398-7405.
25.
Sfanos KS, Bruno TC, Maris CH, et al. Phenotypic analysis of prostate-infiltrating lymphocytes reveals T(H)17 and T-reg skewing. Clin Cancer Res 2008; 14: 3254-3261.
26.
Balkwill F, Charles KA, Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 2005; 7: 211-217.
27.
Sfanos KS, Bruno TC, Meeker AK, et al. Human Prostate-Infiltrating CD8(+) T Lymphocytes are Oligoclonal and PD-1+. Prostate 2009; 69: 1694-1703.
28.
Kiniwa Y, Miyahara Y, Wang HY, et al. CD8(+) Foxp3(+) regulatory T cells mediate immunosuppression in prostate cancer. Clin Cancer Res 2007; 13: 6947-6958.
29.
Di Carlo E, D’Antuono T, Pompa P, et al. The Lack of Epithelial Interleukin-7 and BAFF/BLyS gene expression in prostate cancer as a possible mechanism of tumor escape from immunosurveillance. Clin Cancer Res 2009; 15: 2979-2987.
30.
Sorrentino C, Musiani P, Pompa P, et al. Androgen deprivation boosts prostatic infiltration of cytotoxic and regulatory T lymphocytes and has no effect on disease-free survival in prostate cancer patients. Clin Cancer Res 2011; 17: 1571-1581.
31.
Woo JR, Liss MA, Muldong MT, et al. Tumor infiltrating B-cells are increased in prostate cancer tissue. J Transl Med 2014; 12: 30-39.
Share
RELATED ARTICLE
| eISSN: | 2084-9869 |
| ISSN: | 1233-9687 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
